Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular just downgraded at Morgan Stanley, here's why
09:58am, Monday, 13'th Jan 2025
Intra-Cellular +32.2 (+33.94%) Johnson & Johnson +1.38 (+0.97%)
Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B
09:25am, Monday, 13'th Jan 2025
Shares of Intra-Cellular Therapies (ITCI) are surging 35% in premarket trading Monday after Johnson & Johnson (JNJ) said it will acquire the biopharmaceutical company for roughly $14.6 billion.
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders
08:06am, Monday, 13'th Jan 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) to Johnson & Johnson for $132.00 per share
Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?
06:56am, Monday, 13'th Jan 2025
Intra-Cellular (ITCI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te
J&J to buy Intra-Cellular Therapies for $14.6 billion
06:38am, Monday, 13'th Jan 2025
Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion, boosting its presence in the market for neurological disorder treatments.
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
06:32am, Monday, 13'th Jan 2025
Acquisition includes CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of sc
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
06:30am, Monday, 13'th Jan 2025
NEW BRUNSWICK, N.J. & BEDMINSTER, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreem
Johnson & Johnson eyes $10bn acquisition of Intra-Cellular Therapies
04:16am, Monday, 13'th Jan 2025
Johnson & Johnson (NYSE:JNJ) is reportedly in talks to acquire neuroscience-focused biotech firm Intra-Cellular Therapies for $10bn. If completed, the deal would mark the largest biotech acquisition s
J&J explores bid for Intra-Cellular Therapies, Bloomberg News reports
04:35pm, Sunday, 12'th Jan 2025
Johnson & Johnson is exploring a bid to acquire Intra-Cellular Therapies Inc , a biopharmaceutical company, Bloomberg News reported on Sunday citing people familiar with the matter.
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
06:30am, Friday, 10'th Jan 2025
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for ce
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 06'th Jan 2025
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cent
Presentations complement topline data with new data from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy for the treatment of major depressive disorder
Intra-Cellular Therapies: Parkinson's Disease Drug Expansion Could Be The Next Huge Move
10:34pm, Sunday, 08'th Dec 2024
CAPLYTA showed strong revenue growth, with Q3 2024 net product revenues of $125.8 million, which was a 39% year-over-year increase. Potential revenue boost if CAPLYTA's label is expanded to include it
ITCI Submits sNDA to the FDA for Expanded Use of Caplyta in MDD
01:00pm, Wednesday, 04'th Dec 2024
Intra-Cellular submits an sNDA to the FDA, seeking the label expansion of Caplyta to treat MDD in adults as an adjunctive therapy to antidepressants.
BEDMINSTER, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for cen
